GLP-1 Receptor Agonist Companies, Corporate Milestones, Corporate Growth and Development Strategy, Mergers and Acquisitions (M&A)

GLP-1 Receptor Agonist Top Companies and Strategic Involvements

The global GLP-1 receptor agonist market size is calculated at USD 53.5 billion in 2024, grew to USD 62.86 billion in 2025, and is projected to reach around USD 268.37 billion by 2034. The market is expanding at a CAGR of 17.5% between 2025 and 2034.

Top Companies in the GLP-1 Receptor Agonist

• Amneal Pharmaceuticals
• Ascendis Pharma
• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly & Company
• Hansoh Pharma
• Innovent Biologics
• Merck
• Metsera, Inc.
• Novo Nordisk A/S
• Pfizer, Inc.
• Sanofi
• Viking Therapeutics, Inc.

Recent Developments in the GLP-1 Receptor Agonist Market

• In January 2025, Viking Therapeutics, Inc. announced the initiation of a phase 2 clinical trial involving oral VK2735, a dual GLP-1 and GIP receptor agonist. The trial is a randomized, double-blind, placebo-controlled multicenter study to evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy.
• In January 2025, researchers from Medication Weight Loss Clinic, Ireland, found that GLP-1 agonists showed positive results in managing co-occurring obesity and reducing alcohol intake. The reduction in alcohol intake for high consumers was 68%.

GLP-1 Receptor Agonist Market: U.S. Shipment and Product Details